Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
Lung cancer has the highest morbidity rate among all malignant tumors in men and the highest mortality rate in men and women in Russia. In total, 49 145 new cases of lung cancer were registered (diagnosed) in Russia in 2019. The majority of cases are related to exogenic carcinogens and mainly tobacc...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a0745ce3a3d34da8b1d40865cb268cd1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:a0745ce3a3d34da8b1d40865cb268cd1 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:a0745ce3a3d34da8b1d40865cb268cd12021-11-30T16:55:01ZMalignant neoplasm of the bronchi and lung: Russian clinical guidelines1815-14341815-144210.26442/18151434.2021.3.201048https://doaj.org/article/a0745ce3a3d34da8b1d40865cb268cd12021-11-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/87960/66096https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Lung cancer has the highest morbidity rate among all malignant tumors in men and the highest mortality rate in men and women in Russia. In total, 49 145 new cases of lung cancer were registered (diagnosed) in Russia in 2019. The majority of cases are related to exogenic carcinogens and mainly tobacco smoke. For several decades surgical resection with preoperative cytotoxic therapy was an optimal approach for maximal cure rate. This year recommendations were updated with new strategies including adjuvant anti-PD-L1 atezolizumab following completion of chemotherapy in PD-L1 positive patients and osimertinib for EGFR mutated cases. For this moment available data suggest the increase in disease free survival. Strategic approach to treatment for inoperable patients varies according to the status of driver mutations. New approach includes pretreatment option of testing for a wide spectrum of alterations with NGS based panels. Significant changes were incorporated into treatment of ALK mutated NSCLC with two new options of brigatinib for TKI naive patients and lorlatinib for those who progress on second generation drugs. Treatment strategy for patients without activating mutations is based on PD-L1 status. Tsis year recommendations included atezolizumab as a new monotherapy option for patients with high depression of PD-L1. Also treatment options for pembrolizumab, nivolumab and atezolizimab were widened with prolonged treatment schedules.Konstantin K. LaktionovElena V. ArtamonovaTatiana N. BorisovaValerii V. BrederIurii M. BychkovLiubov Iu. VladimirovaNikita M. VolkovStepan M. ErgnianAlbina S. ZhabinaPavel V. KononetsAleksandr E. Kuz’minovEvgenii V. LevchenkoOlga A. MalikhovaDimitr T. MarinovSergei V. MillerFedor V. MoiseenkoValeriia V. Mochal’nikovaSergei N. NovikovOleg V. PikinElena V. ReutovaEvgenii O. RodionovDina D. SakaevaAnna I. SemenovaAleksei V. SmolinVladimir M. SotnikovSergei A. TuzikovIgor N. TurkinIgor E. TiurinVladimir D. ChkhikvadzeKonstantin I. KolbanovAndrei V. ChernichenkoAleksandr A. FedenkoElena V. FilonenkoAleksei A. Nevol’skikhSergei A. IvanovZhanna V. KhailovaTigran G. GevorkianAleksei V. ButenkoIlmira R. Gil’mutdinovaIrina V. GridnevaMikhail A. EremushkinMargarita A. ZernovaBoris S. KasparovDenis V. KovlenKristina O. Kondrat’evaTatiana V. KonchugovaSvetlana B. KorotkovaAnton A. KrutovOlga A. ObukhovaGennadii N. PonomarenkoTatiana Iu. SemiglazovaAleksandra M. StepanovaGalina A. TkachenkoMarina M. KhulamkhanovaIP Habib O.N.articlelung cancerclinical guidelinesNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 3, Pp 369-402 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
RU |
topic |
lung cancer clinical guidelines Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
spellingShingle |
lung cancer clinical guidelines Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Konstantin K. Laktionov Elena V. Artamonova Tatiana N. Borisova Valerii V. Breder Iurii M. Bychkov Liubov Iu. Vladimirova Nikita M. Volkov Stepan M. Ergnian Albina S. Zhabina Pavel V. Kononets Aleksandr E. Kuz’minov Evgenii V. Levchenko Olga A. Malikhova Dimitr T. Marinov Sergei V. Miller Fedor V. Moiseenko Valeriia V. Mochal’nikova Sergei N. Novikov Oleg V. Pikin Elena V. Reutova Evgenii O. Rodionov Dina D. Sakaeva Anna I. Semenova Aleksei V. Smolin Vladimir M. Sotnikov Sergei A. Tuzikov Igor N. Turkin Igor E. Tiurin Vladimir D. Chkhikvadze Konstantin I. Kolbanov Andrei V. Chernichenko Aleksandr A. Fedenko Elena V. Filonenko Aleksei A. Nevol’skikh Sergei A. Ivanov Zhanna V. Khailova Tigran G. Gevorkian Aleksei V. Butenko Ilmira R. Gil’mutdinova Irina V. Gridneva Mikhail A. Eremushkin Margarita A. Zernova Boris S. Kasparov Denis V. Kovlen Kristina O. Kondrat’eva Tatiana V. Konchugova Svetlana B. Korotkova Anton A. Krutov Olga A. Obukhova Gennadii N. Ponomarenko Tatiana Iu. Semiglazova Aleksandra M. Stepanova Galina A. Tkachenko Marina M. Khulamkhanova Malignant neoplasm of the bronchi and lung: Russian clinical guidelines |
description |
Lung cancer has the highest morbidity rate among all malignant tumors in men and the highest mortality rate in men and women in Russia. In total, 49 145 new cases of lung cancer were registered (diagnosed) in Russia in 2019. The majority of cases are related to exogenic carcinogens and mainly tobacco smoke. For several decades surgical resection with preoperative cytotoxic therapy was an optimal approach for maximal cure rate. This year recommendations were updated with new strategies including adjuvant anti-PD-L1 atezolizumab following completion of chemotherapy in PD-L1 positive patients and osimertinib for EGFR mutated cases. For this moment available data suggest the increase in disease free survival. Strategic approach to treatment for inoperable patients varies according to the status of driver mutations. New approach includes pretreatment option of testing for a wide spectrum of alterations with NGS based panels. Significant changes were incorporated into treatment of ALK mutated NSCLC with two new options of brigatinib for TKI naive patients and lorlatinib for those who progress on second generation drugs. Treatment strategy for patients without activating mutations is based on PD-L1 status. Tsis year recommendations included atezolizumab as a new monotherapy option for patients with high depression of PD-L1. Also treatment options for pembrolizumab, nivolumab and atezolizimab were widened with prolonged treatment schedules. |
format |
article |
author |
Konstantin K. Laktionov Elena V. Artamonova Tatiana N. Borisova Valerii V. Breder Iurii M. Bychkov Liubov Iu. Vladimirova Nikita M. Volkov Stepan M. Ergnian Albina S. Zhabina Pavel V. Kononets Aleksandr E. Kuz’minov Evgenii V. Levchenko Olga A. Malikhova Dimitr T. Marinov Sergei V. Miller Fedor V. Moiseenko Valeriia V. Mochal’nikova Sergei N. Novikov Oleg V. Pikin Elena V. Reutova Evgenii O. Rodionov Dina D. Sakaeva Anna I. Semenova Aleksei V. Smolin Vladimir M. Sotnikov Sergei A. Tuzikov Igor N. Turkin Igor E. Tiurin Vladimir D. Chkhikvadze Konstantin I. Kolbanov Andrei V. Chernichenko Aleksandr A. Fedenko Elena V. Filonenko Aleksei A. Nevol’skikh Sergei A. Ivanov Zhanna V. Khailova Tigran G. Gevorkian Aleksei V. Butenko Ilmira R. Gil’mutdinova Irina V. Gridneva Mikhail A. Eremushkin Margarita A. Zernova Boris S. Kasparov Denis V. Kovlen Kristina O. Kondrat’eva Tatiana V. Konchugova Svetlana B. Korotkova Anton A. Krutov Olga A. Obukhova Gennadii N. Ponomarenko Tatiana Iu. Semiglazova Aleksandra M. Stepanova Galina A. Tkachenko Marina M. Khulamkhanova |
author_facet |
Konstantin K. Laktionov Elena V. Artamonova Tatiana N. Borisova Valerii V. Breder Iurii M. Bychkov Liubov Iu. Vladimirova Nikita M. Volkov Stepan M. Ergnian Albina S. Zhabina Pavel V. Kononets Aleksandr E. Kuz’minov Evgenii V. Levchenko Olga A. Malikhova Dimitr T. Marinov Sergei V. Miller Fedor V. Moiseenko Valeriia V. Mochal’nikova Sergei N. Novikov Oleg V. Pikin Elena V. Reutova Evgenii O. Rodionov Dina D. Sakaeva Anna I. Semenova Aleksei V. Smolin Vladimir M. Sotnikov Sergei A. Tuzikov Igor N. Turkin Igor E. Tiurin Vladimir D. Chkhikvadze Konstantin I. Kolbanov Andrei V. Chernichenko Aleksandr A. Fedenko Elena V. Filonenko Aleksei A. Nevol’skikh Sergei A. Ivanov Zhanna V. Khailova Tigran G. Gevorkian Aleksei V. Butenko Ilmira R. Gil’mutdinova Irina V. Gridneva Mikhail A. Eremushkin Margarita A. Zernova Boris S. Kasparov Denis V. Kovlen Kristina O. Kondrat’eva Tatiana V. Konchugova Svetlana B. Korotkova Anton A. Krutov Olga A. Obukhova Gennadii N. Ponomarenko Tatiana Iu. Semiglazova Aleksandra M. Stepanova Galina A. Tkachenko Marina M. Khulamkhanova |
author_sort |
Konstantin K. Laktionov |
title |
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines |
title_short |
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines |
title_full |
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines |
title_fullStr |
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines |
title_full_unstemmed |
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines |
title_sort |
malignant neoplasm of the bronchi and lung: russian clinical guidelines |
publisher |
IP Habib O.N. |
publishDate |
2021 |
url |
https://doaj.org/article/a0745ce3a3d34da8b1d40865cb268cd1 |
work_keys_str_mv |
AT konstantinklaktionov malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT elenavartamonova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT tatiananborisova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT valeriivbreder malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT iuriimbychkov malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT liuboviuvladimirova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT nikitamvolkov malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT stepanmergnian malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT albinaszhabina malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT pavelvkononets malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT aleksandrekuzminov malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT evgeniivlevchenko malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT olgaamalikhova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT dimitrtmarinov malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT sergeivmiller malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT fedorvmoiseenko malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT valeriiavmochalnikova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT sergeinnovikov malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT olegvpikin malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT elenavreutova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT evgeniiorodionov malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT dinadsakaeva malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT annaisemenova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT alekseivsmolin malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT vladimirmsotnikov malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT sergeiatuzikov malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT igornturkin malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT igoretiurin malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT vladimirdchkhikvadze malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT konstantinikolbanov malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT andreivchernichenko malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT aleksandrafedenko malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT elenavfilonenko malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT alekseianevolskikh malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT sergeiaivanov malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT zhannavkhailova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT tigranggevorkian malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT alekseivbutenko malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT ilmirargilmutdinova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT irinavgridneva malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT mikhailaeremushkin malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT margaritaazernova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT borisskasparov malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT denisvkovlen malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT kristinaokondrateva malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT tatianavkonchugova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT svetlanabkorotkova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT antonakrutov malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT olgaaobukhova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT gennadiinponomarenko malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT tatianaiusemiglazova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT aleksandramstepanova malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT galinaatkachenko malignantneoplasmofthebronchiandlungrussianclinicalguidelines AT marinamkhulamkhanova malignantneoplasmofthebronchiandlungrussianclinicalguidelines |
_version_ |
1718406461881581568 |